Arovella Therapeutics Limited (ASX:ALA)
Australia · Delayed Price · Currency is AUD 0.0650
+0.0010 (1.56%)
Aug 21, 2026, 3:57 PM AEST
Arovella Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 14.35 | 20.88 | 12.71 | 5.18 | 6.07 |
Cash & Short-Term Investments | 14.35 | 20.88 | 12.71 | 5.18 | 6.07 |
Cash Growth | -31.25% | 64.20% | 145.67% | -14.75% | -9.62% |
Accounts Receivable | - | - | - | 0.01 | 0.04 |
Other Receivables | - | 0.11 | 0.18 | 0 | 0 |
Receivables | - | 0.11 | 0.18 | 0.01 | 0.04 |
Prepaid Expenses | - | 0.11 | 0.21 | 0.03 | 0.06 |
Other Current Assets | 0.3 | 0.07 | 0.05 | 0.2 | 0.42 |
Total Current Assets | 14.66 | 21.17 | 13.15 | 5.42 | 6.59 |
Property, Plant & Equipment | 0.35 | 0.43 | 0.13 | 0.05 | 0.37 |
Other Intangible Assets | - | - | - | - | 0.13 |
Long-Term Deferred Charges | - | - | - | - | 2.12 |
Total Assets | 15.01 | 21.6 | 13.28 | 5.47 | 9.21 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.72 | 0.94 | 0.98 | 0.77 | 0.75 |
Accrued Expenses | - | 0.13 | 0.08 | 0.3 | 0.28 |
Current Portion of Leases | - | - | - | - | 0.07 |
Current Unearned Revenue | - | - | 0.14 | 0.15 | 0.34 |
Other Current Liabilities | 0.12 | 0.42 | 0.84 | 0.45 | 0.06 |
Total Current Liabilities | 0.84 | 1.49 | 2.04 | 1.68 | 1.51 |
Long-Term Leases | - | - | - | - | 0.08 |
Other Long-Term Liabilities | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 |
Total Liabilities | 0.86 | 1.52 | 2.06 | 1.69 | 1.6 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 121.27 | 120.13 | 104.3 | 88.87 | 83.54 |
Retained Earnings | -108.62 | -102.84 | -95.51 | -87.06 | -77.02 |
Comprehensive Income & Other | 1.5 | 2.79 | 2.44 | 1.96 | 1.11 |
Shareholders' Equity | 14.15 | 20.08 | 11.23 | 3.78 | 7.62 |
Total Liabilities & Equity | 15.01 | 21.6 | 13.28 | 5.47 | 9.21 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | - | - | - | - | 0.14 |
Net Cash (Debt) | 14.35 | 20.88 | 12.71 | 5.18 | 5.93 |
Net Cash Growth | -31.25% | 64.20% | 145.67% | -12.67% | -10.72% |
Net Cash Per Share | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
Filing Date Shares Outstanding | 1,189 | 1,189 | 1,051 | 849.91 | 669.84 |
Total Common Shares Outstanding | 1,189 | 1,189 | 1,051 | 849.91 | 669.84 |
Working Capital | 13.82 | 19.68 | 11.11 | 3.74 | 5.08 |
Book Value Per Share | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 |
Tangible Book Value | 14.15 | 20.08 | 11.23 | 3.78 | 7.48 |
Tangible Book Value Per Share | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 |
Machinery | - | 0.71 | 0.34 | 0.25 | 1.07 |